CN Patent

CN110869022A — 使用维贝隆以治疗膀胱过度活动症

Assigned to Sumitomo Pharmaceutical Suzhou Co Ltd · Expires 2020-03-06 · 6y expired

What this patent protects

本披露内容涉及一种治疗膀胱过度活动症的方法，该方法包括每天向有需要的受试者口服施用从约60mg至约90mg(例如，约75mg)的量的维贝隆。本披露内容还涉及一种用于口服施用的药物单位剂量组合物，该药物单位剂量组合物包含从约60mg至约90mg(例如，约75mg)的维贝隆。

USPTO Abstract

本披露内容涉及一种治疗膀胱过度活动症的方法，该方法包括每天向有需要的受试者口服施用从约60mg至约90mg(例如，约75mg)的量的维贝隆。本披露内容还涉及一种用于口服施用的药物单位剂量组合物，该药物单位剂量组合物包含从约60mg至约90mg(例如，约75mg)的维贝隆。

Drugs covered by this patent

Patent Metadata

Patent number
CN110869022A
Jurisdiction
CN
Classification
—
Expires
2020-03-06
Drug substance claim
No
Drug product claim
No
Assignee
Sumitomo Pharmaceutical Suzhou Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.